Alton, EW, Armstrong, DK, Ashby, D, Bayfield, KJ, Bilton, D, Bloomfield, EV
, Boyd, AC, Brand, J, Buchan, R, Calcedo, R, Carvelli, P, Chan, M, Cheng, SH
, Collie, DS, Cunningham, S, Davidson, HE, Davies, G, Davies, JC, Davies, LA, Dewar, MH
, Doherty, A, Donovan, J, Dwyer, NS, Elgmati, HI, Featherstone, RF, Gavino, J, Gea-sorli, S, Geddes, DM, Gibson, JS, Gill, DR, Greening, AP, Griesenbach, U, Hansell, DM, Harman, K, Higgins, TE, Hodges, SL, Hyde, SC
, Hyndman, L, Innes, JA, Jacob, J, Jones, N, Keogh, BF, Limberis, MP, Lloyd-evans, P, Maclean, AW, Manvell, MC, Mccormick, D, Mcgovern, M
, Mclachlan, G, Meng, C, Montero, MA, Milligan, H, Moyce, LJ
, Murray, GD, Nicholson, AG, Osadolor, T, Parra-leiton, J, Porteous, DJ, Pringle, IA, Punch, EK, Pytel, KM, Quittner, AL, Rivellini, G, Saunders, CJ, Scheule, RK, Sheard, S, Simmonds, NJ, Smith, K, Smith, SN, Soussi, N, Soussi, S, Spearing, EJ, Stevenson, BJ, Sumner-jones, SG, Turkkila, M, Ureta, RP, Waller, MD, Wasowicz, MY, Wilson, JM & Wolstenholme-hogg, P 2016,
A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. Efficacy and Mechanism Evaluation, no. 5, vol. 3, vol. 3, NHS National Institute for Health Research.
https://doi.org/10.3310/eme03050